retatrutide regulatory approval A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity FDA approves Retatrutide this year?

Testosterone deficiency worsens mitochondrial dysfunction in APP/PS1 mice

Defining realistic treatment goals with your doctor A successful sermorelin therapy journey begins with a clear and honest conversation with your doctor about your health goals

Our studies identify a histone acetylation pathway promoted by KG production that is indispensable for HR proficiency and corresponding resistance to DNA-damaging agents

Combining cost transparency, genetic context, and biomarker awareness helps you have a more complete conversation with your provider

Unlike traditional GLP-1 therapies, Retatrutide works by targeting three hormone receptors involved in appetite control, blood sugar regulation, and energy balance: GLP-1, GIP, and glucagon receptors